The FDA has approved Janssen’s Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia. The once-daily oral medication is specifically designed to deliver paliperidone — the active ingredient derived from risperidone — through the innovative OROS(R) extended-release technology, demonstrating powerful efficacy and a proven safety and tolerability profile. The FDA approved BioForm Medical’s Radiesse, a cosmetic dermal filler for the long-lasting correction of moderate to severe facial wrinkles and folds. Radiesse also received FDA approval for the correction of facial fat loss in patients with HIV.
Product news from the 01/02/07 news brief
The FDA has approved Janssen’s Invega (paliperidone) extended-release tablets, a new atypical antipsychotic, for the treatment of schizophrenia.